Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Editorial

Epidemiology, costs, and the economic burden of fibromyalgia

Michael Spaeth

Author Affiliations

Rheumatologische Schwerpunktpraxis, Bahnhofstra├če 95, 82166 Graefelfing, Munich, Germany

Arthritis Research & Therapy 2009, 11:117  doi:10.1186/ar2715


See related research by Sicras-Mainar et al., http://arthritis-research.com/content/11/2/R54

Published: 30 June 2009

Abstract

The assumption that fibromyalgia is associated with a major impact on the utilization of both healthcare and nonhealthcare resources has not been thoroughly supported by evidence-based data. Despite the differences between healthcare and sociopolitical systems in various countries, more recent results from epidemiological research now clearly demonstrate the socioeconomic burden of fibromyalgia and its comorbidities. The costs of the disease, calculated in single studies and countries, allow estimates for populations in other countries. The alarming results highlight the urgent need both for more research (including pathophysiology and epidemiology) and for the acceptance of emerging treatment challenges.